As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an inside look on what is on the industry’s radar. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- Baxter
- Large-scale biomanufacturing expansions continue
- Samsung Biologics
- Lotte Biologics
- Fujifilm Diosynth Biotechnologies
- Lonza
- WuXi Biologics
- Expansions in Peptides and Oligonucleotides Ramp Up
- Bachem
- Agilent Technologies
- WuXi STA
- CordenPharma
- New CDMOs Enter the Market
- eureKING
- NewBiologix
- Ascend Gene & Cell Therapies
Podcast Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show
Support the show
Support the show
Information
- Show
- Published14 June 2023 at 18:00 UTC
- Length23 min
- RatingClean